Schonfeld Strategic Advisors LLC Cti Biopharma Corp Transaction History

Schonfeld Strategic Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $865,670 - $1.24 Million	206,112 Added 11.79%	1,953,712 $8.21 Million
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $1.86 Million - $2.58 Million	418,124 Added 31.45%	1,747,600 $10.5 Million
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $2.58 Million - $3.58 Million	481,776 Added 56.83%	1,329,476 $7.74 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $2.27 Million - $4 Million	638,100 Added 304.44%	847,700 $5.06 Million
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $72,960 - $200,832	38,400 Added 22.43%	209,600 $978,000
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.86 $137,088 - $272,272	95,200 Added 125.26%	171,200 $424,000
Q3 2021 Nov 16, 2021	SELL	$2.25 - $3.18 $2,250 - $3,180	-1,000 Reduced 1.3%	76,000 $224,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $2.62 $78,783 - $95,561	36,474 Added 90.0%	77,000 $193,000
Q1 2021 May 17, 2021	SELL	$2.68 - $3.8 $12,258 - $17,381	-4,574 Reduced 10.14%	40,526 $117,000
Q4 2020 Feb 16, 2021	BUY	$2.48 - $3.8 $111,848 - $171,380	45,100 New	45,100 $145,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.